Forbion Growth Fund III

Forbion Growth Opportunities Fund III is a €1.2 billion investment vehicle managed by Forbion, a leading European life sciences venture capital firm. The fund is specifically designed to invest in late-stage life sciences companies, targeting both private and public entities that have reached clinical-stage development. It focuses on high-impact therapeutic areas such as oncology, cardiovascular disease, and rare diseases, supporting the development of innovative modalities including biologics and gene therapies. By providing significant growth capital, the fund aims to help companies scale their operations and advance their lead programs through pivotal trials and towards commercialization. The fund reached its hard cap in 2024, reflecting strong investor confidence in Forbion's strategy and the European biotech ecosystem.